This paper will make a brief statement from its development stage and intervention process. First, from 1999, a biologist first announced that mesenchymal stem cells have the potential of multi-differentiation, which caused an uproar all over the world, and then all countries strongly supported the clinical research of mesenchymal stem cells in the field of life sciences.

So far, there have been thousands of clinical cases of mesenchymal stem cells intervening in diabetes all over the world. These public cases show that stem cells intervening in diabetes can indeed reverse the condition of diabetic patients to a certain extent, and the dependence on insulin is greatly reduced. After long-term follow-up of patients after treatment, patients receiving this therapy can no longer rely on insulin for up to 3 years. There are no obvious adverse reactions in clinic.

So from this aspect, stem cell intervention in diabetes is a real clinical application, but on the other hand, it is also illusory. Because, although this stem cell therapy has been clinically verified, after all, compared with the number of hundreds of millions of diabetic patients in China, there are only a few thousand cases, and it is difficult to comprehensively simulate and analyze the disease model. And the follow-up time of the patients did not exceed 10 years, so it is not clear whether the patients who received this therapy once will have other adverse hazards after 10 years.